Rise Therapeutics is engaged in discovery, development, GMP manufacturing, and clinical development Live Biotherapeutic Products (LBPs). With our novel Tripartite X (TPX) oral biologics delivery platform that enables us to create functionally directed probiotics, we have the ability to harness traditional biologics treatment strategies to evolve novel oral microbiome-based drugs. Located in Rockville, Maryland, Rise Therapeutics has a current pipeline of four immunologically targeted drug candidates that are poised for Phase 1 clinical development, focused on a range of therapeutic areas including IBD, oncology, autoimmunity, and infectious disease. Rise Therapeutics is in the process of identifying partners and investors to help support clinical proof-of-concept studies for these programs. Moreover, we are leveraging our state-of-the-art GMP manufacturing facility and microbiome product expertise as a sponsor to help advance other early-stage companies via partnership or CDMO models.
Rise Therapeutics, LLC is presenting as part of the NIH Innovation Zone.